41st week of 2009 patent applcation highlights part 43 |
Patent application number | Title | Published |
20090253737 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Provided are certain chemical entities, and methods of use to modulate skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and methods of use in the treatment of neuromuscular disorders, conditions having muscle wasting, claudication, frailty, metabolic syndrome, muscle atrophy associated with disuse, and muscle fatigue, and other indications. | 2009-10-08 |
20090253738 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS - The present invention discloses triazolopyridinone derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: | 2009-10-08 |
20090253739 | Amine Derivatives - The invention relates to compounds of formula (1) | 2009-10-08 |
20090253740 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS - This invention provides a compound of the formula (I): And their use for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound. | 2009-10-08 |
20090253741 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS - This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with alkene piperidine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS. | 2009-10-08 |
20090253742 | MARASMIUS ANDROSACEUS L.ES FR EXTRACT, PIPERIDONE DERIVATIVE, AND THEIR USE FOR THE PREPARATION OF ANTIHYPERTENSIVES - The present invention relates to | 2009-10-08 |
20090253743 | COMPOSITIONS OF TOLPERISONE - The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features. | 2009-10-08 |
20090253744 | Acylated piperidine derivatives as melanocortin-4 receptor modulators - Certain novel N-acylated spiropiperidine derivatives are ligands of the human melanocortin receptor(s) and, in particular, are selective ligands of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of MC-4R, such as obesity, diabetes, nicotine addiction, alcoholism, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. | 2009-10-08 |
20090253745 | MODULATORS OF OCULAR OXIDATIVE STRESS - Described herein are compounds, compositions and methods directed to the treatment of ophthalmic conditions characterized by oxidative stress or damage in a subject by reducing the reactive oxygen species in the subject. Also described herein are methods for reducing ophthalmic photooxidative damage in a subject. | 2009-10-08 |
20090253746 | Synthesis and Preparations of Intermediates and New Polymorphs Thereof Useful For The Preparation Of Donepezil Hydrochlcoride - The invention relates to an improved process for preparing 2-(1-benzylpiperidin-4-ylmethyliden)-5,6-dimethoxyin-dan- | 2009-10-08 |
20090253747 | Remedy for sleep disturbance - The present invention has been made based on the finding that a compound acting on the ORL-1 receptor as an agonist acts as a non-photic entrainment factor, and advances the circadian rhythm phase, and provides a novel therapeutic agent for a sleep disorder such as circadian rhythm sleep disorder, more particularly, an agent for the prophylaxis and/or treatment of a sleep disorder, which contains an ORL-1 receptor agonist, and a novel compound useful as such agent for the prophylaxis and/or treatment. | 2009-10-08 |
20090253748 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS - A process for the preparation of 14-O-[(N-(3-methyl-2-amino-butyryl-piperidinyl)sulfanyl) acetyl]mutilins of formula (I) feasible for large-scale production of high purity products, and wherein the carbon atom at the piperidine ring attached to the sulphur atom is either in the (S)-configuration or in the (R)-configuration, and a new crystalline form of 14-O-[(N-3-methyl-2-(R)-amino-butyryl-piperidine-3(S)-yl)sulfanyl)acetyl]mutilin-hydrochloride. | 2009-10-08 |
20090253749 | SUBSTITUTED ENAMINOCARBONYL COMPOUNDS - The present invention relates to novel substituted enaminocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects. | 2009-10-08 |
20090253750 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES - The present invention provides 3-indazoyl-4-pyridylisothiazoles or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods of using the same, as well as processes for preparing the same, and intermediates thereof. | 2009-10-08 |
20090253751 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR - Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided. | 2009-10-08 |
20090253752 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFIN - The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises;
| 2009-10-08 |
20090253753 | Therapeutic Use of Acylaminothiazole Derivatives - The present invention discloses and claims therapeutic uses of a compound corresponding to the general formula (I): | 2009-10-08 |
20090253754 | Fast dissolving films and coatings for controlled release of flavors, active pharmaceutical ingredients, food substances, and nicotine - A fast-dissolving film for use as a platform for the delivery of material to the oral cavity, comprising a film forming agent; a plasticizing agent; and a fast-dissolving, water-soluble agent; and methods for producing same. | 2009-10-08 |
20090253755 | N-[(PYRIDIN-2-YL) METHOXY] BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FUNGICIDES - A compound of general formula (I): | 2009-10-08 |
20090253756 | Indole Amide Derivatives as EP4 Receptor Antagonists - The invention is directed to indole amide derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included. | 2009-10-08 |
20090253757 | Plant protection agents - The present invention relates to a microbicide composition for plants, containing at least two active ingredient components in an amount producing synergistic activity, together with an appropriate filler, wherein component I is the compound | 2009-10-08 |
20090253758 | Selective androgen receptor modulators - This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, and or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, Ie, and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds of formulas I, Ia, Ib, Ic, Id, Ie, and intermediates useful in the preparation of same. | 2009-10-08 |
20090253759 | TETRALIN ANALOGS HAVING SPHINGOSINE 1-PHOSPHATE AGONIST ACTIVITY - Tetralin analogs that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at S1P receptors. | 2009-10-08 |
20090253760 | HYDRINDANE ANALOGS HAVING SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST ACTIVITY - Hydrindane analogs that have agonist activity at one or more of the S | 2009-10-08 |
20090253761 | BENZOCYCLOHEPTYL ANALOGS HAVING SPHINGOSINE 1-PHOSPHATE RECEPTOR ACTIVITY - Benzocycloheptyl analogs that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at S1P receptors. | 2009-10-08 |
20090253762 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY - This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases. | 2009-10-08 |
20090253763 | ESTER COMPOUND AND ITS USE - An ester compound represented by the formula (I): | 2009-10-08 |
20090253764 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM - The invention relates to the use of imidazole derivatives of the formula (1): | 2009-10-08 |
20090253765 | Angiogenesis Inhibitor Containing Amine Derivative as Active Ingredient - An object of the present invention is to provide an angiogenesis inhibitor. The angiogenesis inhibitor according to the present invention contains a compound represented by the following general formula [I] or a salt thereof as an active ingredient. In the formula, the ring A represents a benzene ring or a naphthalene ring; X represents a single bond, an alkylene group or —CH | 2009-10-08 |
20090253766 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 2009-10-08 |
20090253767 | AMINOINDAZOLYLUREA DERIVATIVES - Novel aminoindazolylurea derivatives of the formula I (I), in which R | 2009-10-08 |
20090253768 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS - Pyrrole derivatives are disclosed as agents for the treatment and prevention of neuropathies and neurodegenerative diseases characterized by the presence of axonal blockages, impaired axonal transport or impaired trafficking of vesicles in neurons. | 2009-10-08 |
20090253769 | Inhibitors of mammalian hdac 11 useful for treating hdac 11 mediated disorders - The present invention, relies, in part, on the discovery of the role of HDAC 11 in various cell proliferative disorders including cancer. In the main, the invention provides for methods of inhibiting HDAC 11 as a means of treating cell proliferative disorders. Reagents for use in inhibiting human HDAC 11 are also provided. | 2009-10-08 |
20090253770 | Target gene mimitin of myc - A new diagnosis or treatment of cancer is provided. The present invention provides a protein Mimitin which is a target of a cancer gene myc protein, a variant thereof and a fragment thereof, as well as a polynucleotide molecule encoding them. An inhibitory substance of biological activity of the present invention, which is afforded by the binding of a polynucleotide molecule encoding a Mimitin protein and Myc provides a useful means for the diagnosis, prophylaxis or treatment of cancer. | 2009-10-08 |
20090253771 | INHIBITION OF GLIOTOXIN - The present invention relates to the inhibition of the interaction between Gliotoxin (GT) and its intracellular target for the prevention and/or treatment of fungal infections. Further, novel methods and systems for identifying antifungal agents are disclosed. | 2009-10-08 |
20090253772 | RNA INTERFERENCE MEDIATED INHIBITION OF CXCR4 GENE EXPRESSION USING SHORT INTERFERING NUCELEIC ACID (siNA) - This invention relates to compounds, compositions, and methods useful for modulating chemokine receptor (CXCR) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CXCR gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of CXCR genes such as CXCR4 and CXCR7A. | 2009-10-08 |
20090253773 | RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - This invention relates to compounds, compositions, and methods useful for modulating tumor necrosis factor and/or tumor necrosis factor receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of tumor necrosis factor and/or tumor necrosis factor receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of tumor necrosis factor and/or tumor necrosis factor receptor genes, (TNF and/or TNF receptor). | 2009-10-08 |
20090253774 | RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - This invention relates to compounds, compositions, and methods useful for modulating platelet derived growth factor (PDGF) and/or platelet derived growth factor receptor (PDGFr) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of platelet derived growth factor (PDGF) and/or platelet derived growth factor receptor (PDGFr) gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of platelet derived growth factor (PDGF) and/or platelet derived growth factor receptor (PDGFr) genes, such as PDGF and/or PDGFr. | 2009-10-08 |
20090253775 | Compositions and Methods for Therapy and Diagnosis of Cancer and Cancer Metastasis - The present invention relates to methods which make possible to assess and/or prognose a cancer disease, the metastatic behaviour of a cancer disease and/or the occurrence of a relapse of cancer. In particular, the methods of the invention make possible to assess and/or prognose the occurrence of cancer metastasis, in particular distant metastasis. Preferably, the methods of the invention allow to discriminate malign from benign conditions. | 2009-10-08 |
20090253776 | siRNA targeting gremlin - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CKSF1B1. | 2009-10-08 |
20090253777 | Methods of diagnosing and treating hyperproliferative disorders - The invention relates to compositions and methods for diagnosing and treating hyperproliferative disorders using ligands which specifically recognize the hypusine and/or folate binding region of mature eukaryotic translation initiation factor 5A (hypusine-containing eIF-5A). The invention further relates to methods of identifying molecules which displace immunoreagents binding to mature eIF-5A. Such agents are useful for treating hyperproliferative disorders. | 2009-10-08 |
20090253778 | DNA composition against tumor stromal antigen FAP and methods of use thereof - A DNA composition effective for eliciting an immune response against tumor cells and tumor metastases comprising a DNA construct that encodes for at least one epitope of fibroblast activation protein (FAP), which is expressible in immune cells, and which is incorporated in a pharmaceutically acceptable carrier. The composition can encode a single epitope of FAP, a polypeptide comprising two or more epitopes of FAP, the entire FAP protein, or any portion thereof that will elicit the desired immune response. In one preferred embodiment, the composition also includes a DNA construct that encodes an immune effector protein, such as a cytokine. The DNA composition of the invention can be used alone or in combination with a chemotherapeutic agent to treat diseases such as tumors and tumor metastases. | 2009-10-08 |
20090253779 | Expression of Rbap48 in Memory and Aging and Methods Related Thereto - This invention provides a method for increasing the expression of RbAp48 protein in a eukaryotic cell comprising introducing into the cell an agent which specifically increases the expression of RbAp48 protein in the cell. This invention also provides a method for treating a subject afflicted with age-related memory decline comprising administering to the subject a therapeutically effective amount of an agent which specifically increases the expression of RbAp48 protein in the cells of the subject's brain. This invention further provides a method for determining whether an agent causes an increase in the expression of RbAp48 protein. Finally, this invention provides a method for determining whether an agent causes an increase in the activity of RbAp48 protein. | 2009-10-08 |
20090253780 | COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER - The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-16, using miR-16 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA. | 2009-10-08 |
20090253781 | Therapeutic compositions - Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. | 2009-10-08 |
20090253782 | Compounds for Enhancing Arginase Activity and Methods of USe Thereof - The present invention relates to a method for enhancing arginase activity in a damaged or injured cell. In other aspects, the invention provides a method for treating a disorder that can be treated by enhancing arginase activity in a human in need thereof, the method comprising administering to the human an effective amount of a compound that enhances arginase activity. Such disorders include ischemia, hypoxia, neurodegenerative disease or condition, stroke or trauma of the nervous system. In yet another aspect, the invention provides methods for promoting regeneration of a neural cell in a human in need thereof. | 2009-10-08 |
20090253783 | Production of Delta 9 Tetrahydrocannabinol - The present invention provides isolated, purified Δ9 THC. In another embodiment, the invention provides pharmaceutical compositions comprising isolated, purified Δ9 THC and a pharmaceutically acceptable carrier. In another embodiment, the invention provides methods of preparing pharmaceutical compositions comprising isolated, purified Δ9 THC and a pharmaceutically acceptable carrier. | 2009-10-08 |
20090253784 | USE OF 3-(2,4,6-TRIMETHYLPHENYL)-4-NEOPENTYLCARBONYLOXY-5,5-TETRAMETHYLENE- - DELTA3-DIHYDROFURAN-2-ONE FOR CONTROLLING DIPTERA FROM THE CECIDOMYIIDAE FAMILY - The present application relates to the use of 3-(2,4,6-trimethylphenyl)-4-neopentylcarbonyloxy-5,5-tetramethylene-Δ | 2009-10-08 |
20090253785 | Bactericide composition - A bactericide composition kills | 2009-10-08 |
20090253786 | Synthesis, anti-allergic, anti-asthmatic and anti-inflammatory activities of CEE-1 and CEE-2 - “Enhydrazone esters of formula (I): wherein R is methyl or ethyl group have been synthesized. The compounds of formula (I) are potent inhibitors of degranulation of both mast cells and eosinophils. These compounds also suppress cytokines generation by leukocytes. These biological activities are relevant to the prevention and/or treatment of asthma, allergies and inflammatory diseases. It is known to the art that inhibitors of mast cell degranulation such as cromolyn sodium and nedocromil sodium are used in the treatment of asthma and other allergic diseases. Inhibitors of cytokine generation, such as steroids, are also useful in the prevention and treatment of inflammatory diseases as well as asthma and allergies”. | 2009-10-08 |
20090253787 | SHORT-ACTING SEDATIVE HYPNOTIC AGENTS FOR ANESTHESIA AND SEDATION - The invention provides compounds compositions and methods useful for inducing or maintaining general anesthesia or sedation in mammals. | 2009-10-08 |
20090253788 | Combinations of adapalene and benzoyl peroxide for treating acne lesions - Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO. | 2009-10-08 |
20090253789 | Preventive/Remedy for Arteriosclerotic Disease and Method of Evaluating Therapeutic Procedure - There is provided an evaluation method of effect of a remedy or a therapeutic procedure for atherosclerosis directly or indirectly acting on a substance having a nature of exacerbating atherosclerosis (particularly, a protein) and being present in an atherosclerotic lesion to improve the atherosclerotic lesion, which comprises performing an evaluation by, regarding respective atherosclerotic lesion samples of a mammal origin collected from an administration- or application-group of the remedy or therapeutic procedure, and from a non-administration- or non-application-group, comparing a value of one group corresponding to strength of an atherosclerosis-exacerbating activity of the substance (for example, a pharmacological activity such as an enzyme activity) present in the sample and corrected by an amount of a correction marker in the atherosclerotic lesion, with that of the other group, said amount of the correction maker varying correlating with an amount of the substance in the atherosclerotic lesion and being not influenced by the remedy or therapeutic procedure to be evaluated. | 2009-10-08 |
20090253790 | Dairy Composition with Probiotics and Anti-Microbial System - Dairy compositions are provided having a high pH, of about 4.8 to about 6.2, comprising desirable probiotic cultures as well as an anti-microbial system for inhibiting undesirable pathogenic and/or spoilage microbial growth without significantly reducing the beneficial effect of the probiotic cultures. | 2009-10-08 |
20090253791 | Compositions and Methods For Preventing Or Treating Inflammatory Bowel Disease - Compositions comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid (LA), and α-linoleic acid (ALA) are administered to felines for preventing or treating feline inflammatory bowel disease (IBD). | 2009-10-08 |
20090253792 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS - The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions. | 2009-10-08 |
20090253793 | COMPOSITION AND METHOD FOR BINDING ACETALDEHYDE IN STOMACH - This invention relates to a non-toxic composition which bind acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s) comprising one or more free sulphhydryl and/or amino groups. The compound(s) are mixed with a non-toxic carrier that effects sustained release of said compound(s) in the gastrointestinal tract. These compositions are of benefit in particular to patients having atrophic gastritis or achlorhydric or low acid stomach. | 2009-10-08 |
20090253794 | Fibroblast Activator, Collagen Production Promoter, Collagen Contraction Promoter, Hyaluronic Acid Production Promoter, ATP Production Promoter, Melanin Formation Inhibitor, and Agent for External Application to the Skin - The present invention is a fibroblast activator, collagen production promoter, collagen contraction promoter, hyaluronic acid production promoter, ATP production promoter or melanin formation suppressor, which contains, as an active ingredient, at least one kind of compound selected from the group consisting of conagenin, a conagenin derivative, and a pharmaceutically acceptable salt thereof, as well as a composition (skin external preparation, cosmetic, pharmaceutical product or food, which is a composition for the improvement of wrinkles or a whitening composition) containing such activator, promoter or melanin formation suppressor. | 2009-10-08 |
20090253795 | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibiton of pain and inflammation - A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents. | 2009-10-08 |
20090253796 | METHOD FOR TREATING VASCULAR DISEASE - A medicament for prophylactic and/or therapeutic treatment of a vascular disease such as vascular restenosis and/or reocclusion after percutaneous transluminal coronary angioplasty using an intravascular stent, which comprises as an active ingredient a substance selected from the group consisting of retinoids and agents for controlling actions of retinoids such as 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or a salt thereof, or 4-[[[3,5-bis-(trimethylsilyl)phenyl]carbonyl]amino]benzoic acid or a salt thereof, wherein said substance has substantially no antiproliferative action on vascular endothelial cells, but substantially has antiproliferative action on vascular smooth muscle cells. | 2009-10-08 |
20090253797 | CREATINE ORAL SUPPLEMENTATION USING CREATINE HYDROCHLORIDE SALT - Creatine oral supplementation using creatine hydrochloride salt, that may be added to a liquid or other beverage, or may be also used as an additive to solid oral dosages, or as a supplement, and which may be consumed by the athlete, or other party looking for immediate supplementation of strength, and may be added as a supplement within feed to livestock, in the veterinary area. | 2009-10-08 |
20090253798 | COLCHICINE SOLID COMPLEX; METHODS OF MAKING; AND METHODS OF USE THEREOF - Disclosed are new colchicine solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof. | 2009-10-08 |
20090253799 | DIVALENT HYDRAZIDE COMPOUND CONJUGATES FOR INHIBITING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - Provided herein are divalent hydrazide-polyethylene glycol conjugates that inhibit the ion transport activity of a cystic fibrosis transmembrane conductance regulator (CFTR). The conjugates described herein are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased CFTR activity, for example, secretory diarrhea. | 2009-10-08 |
20090253800 | INTERACTION CONTROL OF CATIONIC BIOCIDES USING LABILE ANIONIC POLYELECTROLYTES - Methods of inhibiting the uptake of cationic biocides into medical devices such as contact lenses and implants are described. Methods of stabilizing emulsions containing cationic biocides are also described. In particular, the present invention provides for the use of polymers acting as labile anionic polyelectrolytes to reversibly bind cationic biocides. The reversible binding can reduce the deleterious effects of cationic biocides while maintaining biocidal activity. Preferred polymers include galactomannan and polyvinyl alcohol. | 2009-10-08 |
20090253801 | Novel Antiarrhythmic Drug Formulations - The present invention provides a method of achieving a novel Propafenone formulation, which will have reduced number dosings and improved bioavailability. The present invention also applies to the salt and active metabolites of the parent and pro-drug. The novel compositions are designed to release Propafenone after oral intake in a manner, which enables absorption to take place in the gastrointestinal tract so that a relatively fast peak plasma concentration of the active is obtained. The time-specific pharmaceutical formulation, the disintegration of which is triggered by time lapse and the pH of the environment to which it is subjected. The novel compositions are also designed for administration once or twice daily. i.e. a therapeutically effective concentration of Propafenone is maintained for a period of at least 10-20 hours. A composition is designed to release Propafenone in at least the following consecutive steps: i) an initial relatively fast release of Prop afenone, ii) a second rise in release of Propafenone about 1-6 hours after oral intake; and iii) a third rise in release of Propafenone about 4-15 hours after oral intake, depending upon ones metabolism. | 2009-10-08 |
20090253802 | Therapeutic Agent for Treating liver Disease Containing 2-Amino-1,3-Propanediol Derivative as Active Ingredient, and Method for Treating Liver Disease - A novel therapeutic agent for organ disease, in particular, a therapeutic agent for liver disease is provided. | 2009-10-08 |
20090253803 | MEMANTINE PROTECTS INFLAMMATION-RELATED DEGENERATION OF DOPAMINE NEURONS THROUGH INHIBITION OF OVER-ACTIVATED MICROGLIA AND RELEASE OF NEUROTROPHIC FACTORS FROM ASTROGLIA - This invention discloses that memantine (MMT) protects dopamine (DA) neurons damage through its potent anti-inflammatory effect by inhibiting microglial over-activation and the protection on DA neuron is a dose-dependent response under an effective amount of lower than 10 mg/kg. This invention also discloses that NADPH oxidase plays a critical role of neuroprotection of MMT and MMT therapy for neurodegeneration diseases and disorder acts in part through an alternative novel mechanism by reducing microglia-associated inflammation. In addition, this invention reveals that MMT is neurotrophic to DA neurons through the release of neurotrophic factors from astroglia. | 2009-10-08 |
20090253804 | METHOD FOR TREATING OR PREVENTING DRY EYE DISORDERS USING ALKYLAMINO-POLYHYDROXYALKANES - Method for the treatment or prophylaxis of dry eye disorders by the administration of alkylamino-polyhydroxyalkanes and compositions thereof. | 2009-10-08 |
20090253805 | Photocurable Thiol-Ene Low Gas Permeability Membranes - The present invention provides modified multifunctional thiol-ene monomers wherein one or more thiols are reacted with a Michael addition reactive double bond compound. The present invention further discloses photocurable thiol-ene formulations comprising thiol-ene monomers including the modified multifunctional thiols. The present invention further discloses photocurable thiol-ene formulations comprising thiol-ene monomers and Michael addition reactive double bond molecules and a Michael catalyst. The formulations of the present invention can be photocured to make films or coatings. In a further disclosure, the formulations, including those comprised of unmodified multifunctional thiols and multifunctional enes, are photocured to form films applied to non-flexible or flexible polymer or non-polymer substrates suitable for food packaging, electronic products, optical products and other applications and free-standing films. The present invention further discloses photocurable thiol-ene formulations comprising thiol-ene monomers and Michael addition reactive double bond molecules and a Michael catalyst. These formulations are disclosed to form free-standing films and coatings on substrates when applied to flexible substrates. Such materials are suitable for use in the packaging of food products and other products which are to be maintained in a hermetically sealed relationship to the atmosphere. | 2009-10-08 |
20090253806 | POLYANHYDRIDE POLYMERS AND THEIR USES IN BIOMEDICAL DEVICES - A biocompatible, bioerodable polyanhydride polymer having a Young's modulus between about 1.5 and 3 and a selected rate of surface degradation, and methods of forming and using the polymer, are disclosed. The polymer is formed of a polyester prepolymer having a preferred molecular weight of greater than 5 and less than 7.5 Kdaltons, and a selected number of anhydride linkages between 5 and about 30. | 2009-10-08 |
20090253807 | AQUEOUS SUSPENSION PREPARATIONS - Addition of polyvinylpyrrolidone and a water-soluble anionic macromolecular compound to an aqueous suspension of a hardly soluble drug allows to provide an aqueous suspension in which aggregation of drug particles, formation of macro crystals from suspended particles and formation of secondary particles from deposited particles are prevented, and adhesion and adsorption to containers made of plastics, e.g., polypropylene or polyethylene, are avoided. As it has a good redispersibility, the aqueous suspension is useful as eye drops, nasal drops, ear drops, injections, oral preparations, liniments and lotions. | 2009-10-08 |
20090253808 | TRI-MOLECULAR COMPLEXES AND THEIR USE IN DRUG DELIVERY SYSTEMS - This invention relates to macromolecular complexes useful in drug delivery systems, specifically tri-molecular complexes made between a water-soluble polymer and an acid-insoluble polymer in presence of a bridging molecule. In one aspect, the invention relates to a tri-molecular complex comprising gelatin, acrylic acid/methacrylic acid copolymers, and arginine for use in a soft capsule dosage form. In another aspect, the invention is directed to a tri-molecular complex a hydrophilic, film-forming, water-soluble polymer, a second water-soluble polymer, and a bridging molecule, wherein the second water-soluble polymer is less water-soluble than the hydrophilic, film-forming, water-soluble polymer. | 2009-10-08 |
20090253809 | BIOABSORBABLE ELASTOMERIC POLYMER NETWORKS, CROSS-LINKERS AND METHODS OF USE - The invention provides elastomeric polymer networks and semi-interpenetrating networks in which a linear PEA, PEUR or PEU polymer is crosslinked by ester or alpha-amino-acid containing cross-linkers that polymerize upon exposure to active species. Bioabsorbable elastomeric internal fixation devices fabricated using such polymer networks and semi-interpenetrating networks are useful for in vivo implant and delivery of a variety of different types of molecules in a time release fashion. Alpha-amino-acid containing ester amide cross-linkers are also provided by the invention. | 2009-10-08 |
20090253810 | OSTEOINDUCTIVE PUTTIES AND METHODS OF MAKING AND USING SUCH PUTTIES - The present disclosure relates to osteoinductive putties and other implantable compositions for repair of bone defects and other medical uses. Specifically, the technology pertains to carriers for use in implantable compositions, such as osteoinductive putties. The osteoinductive putties are made entirely from donor tissue such as demineralized bone matrix, and the putties have excellent physical properties. The present disclosure relates to osteoinductive putties, carriers, compositions, implants, kits, methods of making and methods of using any of the foregoing. | 2009-10-08 |
20090253811 | MANUFACTURE PROCESS OF ORGANIC COMPOUNDS - The present invention relates to a method of preparing N-substituted salicylamides or derivatives thereof, and their salts, hydrates and solvates. In particular, the present invention relates to a method of preparing N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC) and its corresponding disodium monohydrate. | 2009-10-08 |
20090253812 | Spider esters as delivery systems - The present invention is directed to the delivery of a variety of topically active materials from a class of compounds called spider esters, which are the topic of U.S. Pat. No. 7,437,707 incorporated herein by reference. According to this first aspect of the present invention, active ingredients are delivered more efficaciously to, and, where desired, through the skin (i.e., localized subdermal penetration). By “delivered more efficaciously” is meant a cream, lotion, gel or serum that is contacted with the skin such that the active ingredient(s) are delivered in a manner that has (i) the same or similar therapeutic effect but at lower dosage of the active ingredient(s), and/or (ii) the same or similar desired therapeutic effect over a longer period of time, and/or (iii) a better or improved therapeutic effect in comparison to the same dose of active ingredient(s) in another delivery vehicle. | 2009-10-08 |
20090253813 | Colloidal silica consisting of silica particles fixing nitrogen contained alkaline compound - A colloidal silica comprising, silica particles inside of which or on the surface of which a nitrogen containing alkaline compound is fixed, wherein said silica particles are prepared by forming and growing colloid particles using the nitrogen containing alkaline compound. Said colloidal silica can be prepared by preparing active silicic acid aqueous solution contacting silicate alkali aqueous solution with cation exchange resin, adding the nitrogen containing alkaline compound and heating, and then growing up particles by build-up method. | 2009-10-08 |
20090253814 | COMPACT REACTOR - The invention relates to a compact reactor that consists of a number of plates that are arranged like stacks and spaced some distance apart, whereby
| 2009-10-08 |
20090253815 | Process and Reactor for Implementing Exothermic and Endothermic Reactions - Implementing at least one endothermic and/or exothermic reaction in a compact reactor which has passages for conducting gaseous and/or liquid media, through which passages the reactants of the endothermic or exothermic reaction as well as a heating medium or coolant are sent, whereby
| 2009-10-08 |
20090253816 | COMPOSITION FOR PREPARING A BIODEGRADABLE POLYURETHANE- BASED FOAM AND A BIODEGRADABLE POLYURETHANE FOAM - Composition for preparing a biodegradable polyurethane-based foam and a biodegradable polyurethane foam, comprising mixtures based on poly(hydroxybutyrate) polymer, polyols of renewable source, isocyanates and additives, with the object of preparing biodegradable polyurethane foams. In the process, the poly(hydroxybutyrate) plus the polyol, the isocyanate and the additives are previously mixed in specific mixers; once the homogenization is reached, the mixture is poured in mold for growing. After curing, the resulting product presents foam characteristics, with its density, toughness and cell size varying according to the proportion of the reagents and allowing the manufacture of several products. | 2009-10-08 |
20090253817 | Polyurethane foams containing silicone surfactants - The present invention relates to polyurethane foam prepared from a polyurethane foam-forming reaction mixture possessing a silicone copolymer surfactant, methods for making the surfactant, and a process for preparing low density polyurethane foams. | 2009-10-08 |
20090253818 | Synthetic Cork Stopper - A synthetic cork stopper which has excellent gas-barrier properties and is satisfactory in sealing properties and suitability for opening. The synthetic cork stopper is obtained by foaming a composition including (a) an isobutylene-based block copolymer comprising a polymer block comprising isobutylene as its main component and a polymer block formed from a cationic polymerizable monomer ingredient in which isobutylene is not its main component; and a foaming agent. | 2009-10-08 |
20090253819 | PROCESS FOR PREPARING POLYURETHANES - The invention relates to a process for the preparation of polyurethanes by reacting polyisocyanates a) with compounds having at least two hydrogen atoms reactive with isocyanate groups b), wherein a polyisocyanate a) used is at least one polyisocyanate ai) having an average functionality of greater than 2, a content of diisocyanates of not more than 2% by weight and a content of uretonimines of not more than 4% by weight, based in each case on the weight of the polyisocyanate ai). | 2009-10-08 |
20090253820 | FOAMING AGENTS AND COMPOSITIONS CONTAINING FLUORINE SUSTITUTED OLEFINS AND METHODS OF FOAMING - Disclosed are bowing agent compositions, foamable compositions, foams, foaming methods and/or foamed articles comprising one or more C2 to C6 fluoroalkenes, more preferably one or more C3 to C5 fluoroalkenes, and even more preferably one or more compounds having Formula I as follows: | 2009-10-08 |
20090253821 | Polyurethane foam with water absorbency and yellowing resistance - A polyurethane foam is obtained by reacting raw materials containing a polyisocyanate, a polyol, a water-absorbency-imparting agent, a catalyst, and a blowing agent, foaming the reaction mixture, and curing the foamed product. The polyol is a polyester polyol. The water-absorbency-imparting agent is a polyoxyalkylene compound having a molecular weight of 100 to 1000 and having a hydroxy group at an end of the molecular chain, or an alcohol with 1 to 8 carbon atoms. The amount of the water-absorbency-imparting agent is from 0.5 to 8 parts by mass per 100 parts by mass of the polyester polyol. The polyisocyanate is an aliphatic polyisocyanate, an alicyclic polyisocyanate, or an aromatic polyisocyanate in which the isocyanate groups are not directly attached to an aromatic ring. The foam has a water absorption ratio of 10 to 30 and a color difference ΔYI of 7 or less. The time required until water dropped onto a surface of the foam is completely absorbed into the foam is 20 seconds or less. | 2009-10-08 |
20090253822 | POLYURETHANE FOAM AND METHOD FOR MANUFACTURING THE SAME - A polyurethane foam is obtained by reacting, foaming, and curing raw material that includes a polyol, a polyisocyanate, a blowing agent, a catalyst, and an inorganic compound hydrate. The raw material includes, as the polyol, a polymeric polyol obtained by graft polymerization of a vinyl monomer onto a polyether polyol and a polyether polyol obtained by addition polymerization of an alkylene oxide to a polyhydric alcohol and having a mass average molecular weight of 400 to 1,000. The blending quantity of the inorganic compound hydrate is 10 to 80 parts by mass per 100 parts by mass of the polyol. Preferably, the raw material further includes, as the polyol, a polyether polyol obtained by addition polymerization of an alkylene oxide to a polyhydric alcohol and has a molecular weight of 2,000 to 4,000. | 2009-10-08 |
20090253823 | Coating composition and method of forming coating film - The present invention provides a thermosetting and photocurable coating composition obtained by incorporating a copolymer of a maleimide group-containing monomer with other monomer(s) or a specific maleimide compound into a composition comprising a hydroxyl-containing resin and a curing agent and optionally containing an unsaturated compound; and a method of forming a coating film using the coating composition. | 2009-10-08 |
20090253824 | Extended stay on wound dressing - A wound dressing composition comprising a highly water-absorbable material (e.g. hydrocolloid), an acrylic adhesive and a tackifier. The composition provides extended stay-on capabilities. The composition also provides an adhesive that is removed from the skin with little pain to the on the skin. | 2009-10-08 |
20090253825 | Dental Filler, Method of Producing the Same, and Dental Composite Material - The present invention provides dental fillers having the optical and/or mechanical characteristics required to dental materials, a method of producing the same, and a dental composite material prepared with use of the dental filler. More specifically, the present invention provides a dental filler containing a zirconium silicate compound, especially a zirconium trisilicate compound with a wadeite type crystalline structure and having an average particle diameter in the range from 2 to 50,000 nm, a method of producing the same, a dental composite material containing the dental filler and a hardenable resin selected from an acrylic resin, a methacrylic resin, an epoxy resin, a vinyl resin, a urethane resin and the like. | 2009-10-08 |
20090253826 | SILVER-CONTAINING POLYURETHANEUREA SOLUTION - The present invention relates to a solution of a nonionic polyurethaneurea, which has a silver-containing component as antimicrobial substance. | 2009-10-08 |
20090253827 | Resin Particle and Resin Dispersion - Resin particles which are excellent in electrostatic property, thermal storage stability and thermal properties, and have evenness of particle diameter are to be provided. The resin particles are core-shell resin particles (C2) each comprising one or more film-like shell layers (P) comprising a first resin (a) and a core layer (Q) comprising a second resin (b). Core-shell type resin particles (C2) each comprising a film-like shell layer (P) in one or more layer structure comprising a first resin (a) and a core layer (Q) in one layer structure comprising a second resin (b), wherein the weight ratio of (P) and (Q) is in a range of (0.1:99.9) to (70:30), the content of volatile components of (C2) is 2% by weight or lower, and (a) has an initial softening temperature of 40 to 270° C., a glass transition temperature of 20 to 250° C., a flow temperature of 60 to 300° C., and the difference of the glass transition temperature and the flow temperature in a range of 0 to 120° C. and contains 20 to 80% by weight of vinyl acetate as constituent units. | 2009-10-08 |
20090253828 | PARTICLE IN THE SHAPE OF AN ENCAPSULATED DROPLET AND PROCESS FOR MAKING SUCH A PARTICLE - Particle in the shape of an encapsulated droplet comprising a core material and a shell material surrounding the core material, the shell material containing maleimide groups, preferably a copolymer of maleimide groups. The shell material contains a copolymer of styrene and maleic anhydride derivatives, of which more than 75 mole %, preferably more than 90 mole % is maleimide, and the average particle size is smaller than 300 nm. The particles are obtained by a process comprising by heating between 80° C. and 195° C., more preferably between 120° C. and 190° C. an ammonium salt of a maleic anhydride containing polymer in the presence of the core material. | 2009-10-08 |
20090253829 | PROCESS FOR THE MANUFACTURING OF SLABS OR BLOCKS OF CONGLOMERATE OF STONE GRANULATE AND POLYESTER RESIN - In the manufacture of articles in slabs or blocks according to so-called Bretonstone technology, a polyester resin is employed, free of reactive solvents, formed by the reaction between an epoxidised triglyceride and at least one carboxylic anhydride. | 2009-10-08 |
20090253830 | METHOD FOR ADDING ANTI-FOAMING AGENT INTO CATIONIC ELECTRODEPOSITION PAINT AND ADDITIVE USED IN THE SAME - A method for stably and effectively adding a hydrophobic anti-foaming agent into the electrodeposition paint is achieved by adding an anti-foaming agent into a cationic electrodeposition paint wherein, when adding the anti-foaming agent to a cationic electrodeposition paint, a dispersion obtained by preliminarily dispersing the anti-foaming agent into a pigment dispersing resin for a cation electrodeposition paint in an amount of 5 to 1,000 parts by weight (solid content) based on 100 parts by weight (solid content) of a pigment dispersing resin is added to the cationic electrodeposition paint. | 2009-10-08 |
20090253831 | Lightweight structure concrete composition - A lightweight structural concrete is composed of coarse structural aggregate sized between ¼ to ½″ occupying 15% to 25% of total concrete volume, large non-structural lightweight aggregate such as expanded polystyrene bead of a particular size distribution and volume amount, small size non-structural lightweight aggregate or entrained air cells of another specific size distribution and volume amount, and a dense cementitious composition comprising cement binder, pozzolan, and fine structural filler no larger than concrete sand ASTM C33. | 2009-10-08 |
20090253832 | COLORANT COMPATIBLE HYDROPHOBICALLY MODIFIED POLYURETHANE THICKENER FOR PAINT - A synthetic polymer has a water-soluble or water-swellable polyurethane backbone and terminal groups and/or intermediate groups of blocks of hydrophobes of alkyl- or aryl compounds containing a polymerizable cyclic monomer or a polymerizable double bond (or alkene) group or derivatives thereof. The blocks of hydrophobes are composed of two or more units of the same or different hydrophobes. These synthetic polymers are used as rheology modifiers, especially in latex paints. | 2009-10-08 |
20090253833 | Liquid Hardening - The present invention relates to a curing agents for air-drying alkyd-based resins, coatings, such as paint, varnish or wood stain, inks and linoleum floor coverings, based on an iron/manganese complex containing tetradentate, pentadentate or hexadentate nitrogen donor ligands. | 2009-10-08 |
20090253834 | ADHESIVE COMPOSITIONS USEFUL IN FLEXIBLE CIRCUIT SUBSTRATE APPLICATIONS AND METHODS RELATING THERETO - This invention is directed to an adhesive composition having ( | 2009-10-08 |
20090253835 | AMINOPLAST RESIN FOR DECORATIVE APPLICATIONS - The present invention relates to an aminoplast resin, suitable for decorative applications and comprising between 0.005 and 5 wt. % of a polyfluorinated (alk-)acrylic polymer, preferably selected from the group consisting of perfluoroalkyl acrylic (co)polymers, perfluoroalkyl methacrylic (co)polymers, and combinations thereof. The present invention further relates to a laminate comprising a top layer and a bottom layer, whereby the top layer comprises an at least partly cured aminoplast resin, characterised in that the top layer comprises between 0.002 and 5 wt. % of a polyfluorinated (alk-)acrylic polymer, preferably selected from the group consisting of perfluoroalkyl acrylic (co)polymers, perfluoroalkyl methacrylic (co)polymers, and combinations thereof. | 2009-10-08 |
20090253836 | FLEXIBLE HIGH THERMOMECHANICAL STRESS-RESISTANT AND FIREPROOF HALOGEN-FREE THERMOPLASTIC COMPOSITIONS - The present invention relates to flame-retarded flexible thermoplastic compositions of high thermomechanical strength, containing no halogen compound, comprising a graft copolymer containing polyamide blocks and composed of a polyolefin backbone and on average at least one polyamide graft, in which the grafts are attached to the backbone by the radicals of an unsaturated monomer (X) having a function capable of reacting with an amine-terminal polyamide, the radicals of the unsaturated monomer (X) being fixed to the backbone by grafting or copolymerization from its double bond, wherein said composition comprises, in a mixture:
| 2009-10-08 |